The expression and clinical significance of different forms of LILRA3 in systemic lupus erythematosus
- 77 Downloads
Our previous study has shown that functional leukocyte immunoglobulin-like receptors A3 (LILRA3) contributes to susceptibility and subphenotypes of systemic lupus erythematosus (SLE). However, the mechanism remains unclear. We aimed to evaluate the role of LILRA3 in SLE.
One hundred twenty-six SLE patients and 48 healthy controls were recruited in this study. Functional studies were performed using intracellular flow cytometry and ELISA.
Both LILRA3 levels in serum and CD14+ monocytes were significantly elevated in SLE patients compared with healthy controls. Elevated LILRA3 level was found positively correlated with SLEDAI. Furthermore, more elevated LILRA3 levels were found in patients with higher SLEDAI, presence of lupus nephritis, and thrombocytopenia.
Both LILRA3 levels in serum and CD14+ monocytes significantly increased in SLE and positively correlated with disease activity and severity. The upregulation of LILRA3 expression may serve as a biomarker of disease activity and severity of SLE.
• LILRA3 contributes to susceptibility and subphenotypes of SLE; LILRA3 is elevated in SLE patients.
• Increased LILRA3 correlated with disease activity and severity.
• LILRA3 may serve as a biomarker of disease activity and severity of SLE.
KeywordsCD14+ monocytes LILRA3 Systemic lupus erythematosus
Study conception and design: Du, Xue, Huaxiang Wu.
Acquisition of data: Du, Fengyin Sun, Xinyu Wu, Zhou, Jiang, Cheng, Xue, Wenjia Sun, Chen, Huaxiang Wu.
Analysis and interpretation of data: Du, Fengyin Sun, Xue, Huaxiang Wu.
Manuscript preparation: Du, Xue, Huaxiang Wu.
Statistical analysis: Du, Fengyin Sun, Huaxiang Wu.
Supported by the National Natural Science Foundation of China (No. 81501388), Zhejiang Provincial Public Technology Applied Research Project (No. 2015C33177, No. 2017C33032, No. LGF19H100003) and Zhejiang Provincial Medical Science and Technology Plan Project (No. 2017KY381).
Compliance with ethical standards
- 5.Hirayasu K, Ohashi J, Tanaka H, Kashiwase K, Ogawa A, Takanashi M, Satake M, Jia GJ, Chimge NO, Sideltseva EW, Tokunaga K, Yabe T (2008) Evidence for natural selection on leukocyte immunoglobulin-like receptors for HLA class I in northeast Asians. Am J Hum Genet 82(5):1075–1083CrossRefGoogle Scholar
- 9.Du Y, Su Y, He J, Yang Y, Shi Y, Cui Y, Luo C, Wu X, Liu X, Hu F, Ma X, Zheng L, Zhang J, Zuo X, Sheng Y, Wu L, Zhang X, Guo J, Li Z (2015) Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjogren's syndrome. Ann Rheum Dis 74(11):2070–2075CrossRefGoogle Scholar
- 14.Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Baranda L, Layseca-Espinosa E, Lopez-Botet M, Gonzalez-Amaro R (2007) Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 29(2–3):97–105CrossRefGoogle Scholar
- 15.Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M (2005) Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 128(Pt 11:2689–2704CrossRefGoogle Scholar
- 16.Kuroki K, Tsuchiya N, Shiroishi M, Rasubala L, Yamashita Y, Matsuta K, Fukazawa T, Kusaoi M, Murakami Y, Takiguchi M, Juji T, Hashimoto H, Kohda D, Maenaka K, Tokunaga K (2005) Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Hum Mol Genet 14(16):2469–2480CrossRefGoogle Scholar
- 18.An H, Chandra V, Piraino B, Borges L, Geczy C, McNeil HP, Bryant K, Tedla N (2010) Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol 37(8):1596–1606CrossRefGoogle Scholar
- 19.Huynh OA, Hampartzoumian T, Arm JP, Hunt J, Borges L, Ahern M, Smith M, Geczy CL, McNeil HP, Tedla N (2007) Down-regulation of leucocyte immunoglobulin-like receptor expression in the synovium of rheumatoid arthritis patients after treatment with disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 46(5):742–751CrossRefGoogle Scholar